Panacea, Refana collaborate on COVID-19 vaccine

By The Science Advisory Board staff writers

June 10, 2020 -- Panacea Biotec and Refana are partnering on an inactivated virus-based vaccine for COVID-19 through a joint venture company that will be based in Ireland.

Panacea will handle product development and commercial manufacturing, and the venture company will be responsible for clinical development and regulatory submissions worldwide. Panacea and Refana will handle sales and distribution of the vaccine in their respective territories.

Refana aims to manufacture over 500 million doses of the COVID-19 vaccine candidate, with over 40 million doses expected to be available for delivery in early 2021.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here